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Introduction: The objective of the present study was to evaluate the capacity of a tissue-engineered complex of
human osteoprotegerin (hOPG)-transfected periodontal ligament stem cells (PDLSCs) seeding on beta-tricalcium
phosphate (β-TCP) to regenerate alveolar bone defects in New Zealand rabbits.
Methods: PDLSCs were isolated from rabbit periodontal ligament tissues and expanded in vitro to enrich PDLSC
numbers, and their proliferative activities and differentiation capability were evaluated under specific induction
conditions. Lentiviral vector containing hOPG and enhanced green fluorescent protein (EGFP) was constructed by
using Gateway technology and transfected into rabbit PDLSCs. The expression of hOPG was determined with
quantitative real-time reverse transcription-polymerase chain reaction and Western blot. The PDLSCs with or without
engineered hOPG were seeded on β-TCP scaffolds prior to transplantation. Morphological characterization of cells
and materials was done by scanning electron microscope. Twenty rabbits with alveolar bone defects were randomly
allocated into four groups and transplanted with β-TCP, PDLSCs/β-TCP, and hOPG-transfected PDLSCs/β-TCP or
were left untreated as a control. Animals were sacrificed 12 weeks after operation for histological observation and
histomorphometric analysis.
Results: PDLSCs expressed STRO-1 and vementin and favored osteogenesis and adipogenesis in conditioned
media. Expressions of hOPG were significantly upregulated after transfection of the lentiviral vector into PDLSCs.
PDLSCs attached and spread well on β-TCP, and there was no significant difference in growth of PDLSCs on β-TCP
between the hOPG transfection group and the non-transfection group. The histological observation and
histomorphometric analysis showed that the hOPG-transfected PDLSCs/β-TCP complex exhibited an earlier
mineralization and more bone formation inside the scaffold than control, β-TCP, and PDLSCs/β-TCP complexes.
Implantation of hOPG-transfected PDLSCs contributed to new bone formation as determined by EGFP gene
expression under circularly polarized light microscopy.
Conclusions: The present study demonstrated the feasibility of β-TCP scaffolds for primary PDLSC culture and
expression of hOPG gene in vitro and in vivo, and hOPG-transfected PDLSCs could serve as a potential cell source
for periodontal bone regeneration, which may shed light on the potential of systemic hOPG gene therapy in
combination with PDLSC tissue engineering as a good candidate in periodontal tissue engineering for alveolar
bone regeneration.* Correspondence: hongchenliu19@163.com
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Periodontal disease, one of the most prevalent chronic
infections in humans, is a highly prevalent chronic in-
flammatory condition involving bacterial infection of
tooth-supporting tissues, which in turn lead to chronic
inflammation and loss of teeth [1]. It has been reported
to be the most common cause of tooth loss in adults, af-
fecting about 90% of the world population [2]. Further-
more, recent evidence has established that periodontal
disease is associated with several systemic conditions, in-
cluding diabetes, cardiovascular disease, stroke, respira-
tory infections, and adverse pregnancy outcomes [3,4].
Therefore, careful treatment of periodontal disease may
be of major importance for oral health as well as im-
provements of long-term outcome of the patients.
Various approaches have been developed to restore the
structure and function of destroyed periodontium, the
final goal of periodontal therapy, and treatments, includ-
ing bone grafting, guided tissue regeneration, and en-
amel matrix derivatives, have already been approved for
clinical use. However, complete regeneration is rarely ac-
complished by these methods [5].
Progress in tissue engineering has offered a new option
to supplement existing treatment regimens for periodontal
disease. Furthermore, the discovery of progenitor/stem
cells residing in the periodontium raises the possibility of
restoring damaged periodontal tissues by recruiting their
latent regenerative potential. Owing to the difficulties en-
countered in isolating specialized cells and the associated
morbidity involved, stem cells serve as a better alternative.
Research in tissue engineering has shown the therapeutic
advantages of delivering stem cells and growth factors in
biodegradable scaffolds, which supply the necessary envir-
onment to recreate a suitable niche for cellular prolifera-
tion and differentiation [6].
Beta-tricalcium phosphate (β-TCP), one of the earliest
calcium compounds used as a bone graft substitute, has
been shown to have good biocompatibility and osteo-
conductivity in both animal and clinical studies [7,8], al-
though the ectopic bone formation following β-TCP
without bone marrow stromal cells or osteoinductive
cytokine implantation has been demonstrated in dogs
[9]. However, no bone formation was observed following
β-TCP implantation into the rat subcutis, and new bone
formation at scaffolds was suggested to depend partially
on the potential of cells in the grafted site [10].
Periodontal ligament stem cells (PDLSCs) with character-
istics of putative mesenchymal stem cells (MSCs) represent
a promising cell-based therapy in reconstructive dentistry
for the treatment of periodontal disease [11]. It can be iso-
lated from periodontal ligament (PDL) cells, providing a
unique reservoir of stem cells from an accessible tissue re-
source. Once isolated, PDLSCs can be expanded suffi-
ciently in vitro and the complex differentiation processesinvolved in periodontal regeneration can be optimized in
the right location. The transplantation of ex vivo-expanded
PDLSCs was suggested to hold promise as a therapeutic
approach for the reconstruction of tissues destroyed by
periodontal diseases [12]. The use of autologous PDLSCs
to treat periodontal defects in animal models of peri-
odontitis has further demonstrated the feasibility of
using PDLSC-mediated tissue engineering to treat
periodontal diseases [13].
Osteoprotegerin (OPG), a member of the tumor ne-
crosis factor (TNF) receptor superfamily of proteins, is a
soluble decoy receptor for RANKL (receptor activator of
nuclear factor-kappa-B ligand), a critical osteoclast dif-
ferentiation factor, and thus prevents binding of RANKL
to RANK and subsequent activation of osteoclast activity
[14]. PDL cells were found to express both RANKL and
OPG mRNA and were suggested to regulate osteoclasto-
genesis by opposing mechanisms—stimulation of resorp-
tive activity by RANKL and inhibition by OPG—thus
affecting processes such as periodontitis and orthodontic
tooth movement [15]. The ratio of RANKL to OPG con-
centration was demonstrated to be significantly higher
for patients with periodontal disease than for healthy
subjects [16]. OPG gene transfer to periodontal tissue
inhibited osteoclastogenesis and alveolar bone resorption
in lipopolysaccharide-induced experimental periodontal
disease [17]. Administration of kaliotoxin, a potassium
channel blocker, markedly decreased the ratio of RANKL
and OPG protein expression and induction of RANKL-
dependent osteoclastogenesis by the activated T cells
in vitro [18]. In vivo inhibition of OPG ligand function
with the decoy receptor OPG diminished alveolar bone
destruction and reduces the number of periodontal oste-
oclasts after microbial challenge [19]. All of these results
identified OPG as a potential therapeutic target for peri-
odontal disease.
Cells, scaffolds, and growth factors are the three main
factors for creating a tissue-engineered construct, and
incorporation of DNA into tissue-engineering matrices
and its subsequent sustained release may provide an op-
timal means to engineer tissues [20]. The biomaterial-
based gene transfer method that combines gene therapy
and tissue engineering to promote tissue regeneration
has been developed. Periodontal tissue engineering using
ex vivo gene transfer has been reported to offer a safe
new approach for repairing periodontal defects [21]. The
objective of this study was to evaluate human OPG
(hOPG) gene-engineered rabbit PDLSCs seeding on β-
TCP scaffolds as prospective candidates for periodontal
tissue engineering. PDLSCs were isolated from rabbit
PDL cells, and their immunophenotype and multipotent
capacity to differentiate into adipocytes, osteoblast-like
cells, were characterized in vitro. Lentiviral vector con-
taining hOPG and enhanced green fluorescent protein
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The expression of hOPG was detected with quantitative
real-time reverse transcription-polymerase chain reaction
(Q-PCR) and Western blot. The β-TCP scaffold combined
with virus encoding hOPG gene was constructed and eval-
uated for cytocompatibility through seeding rabbit periph-
eral and limbal corneal stromal cells (PLCSCs) into
scaffold in vitro. Morphological characterization of cells
and materials was evaluated by scanning electron micro-
scope (SEM). Furthermore, hOPG-transfected PLCSCs-
βTCP scaffolds were implanted into alveolar bone defects




This study was reviewed and approved by the Animal
Ethics Committee of the People’s Liberation Army General
Hospital. Healthy male New Zealand white rabbits, weigh-
ing 2.0 to 2.5 kg, were obtained from the experimental ani-
mal center of our hospital. Animals were maintained under
conventional conditions with free access to food and water.
All surgical procedures and care administered to the an-
imals were approved by the Animal Care Committee and
performed in accordance with institutional guidelines.
Periodontal ligament stem cell cultures
Isolation and cultivation of the rabbit periodontal ligament
stem cells
Rabbits used for isolating PDLSCs were killed after an-
aesthesia by the air embolism method. After the extrac-
tion of disease-free impacted teeth within 2 hours of
death, the surfaces of the teeth were cleaned with 75%
alcohol and PDL cells were gently scraped from the mid-
dle third of the root surface by using forceps and then
digested in a solution of 3 mg/mL collagenase type I
(Sigma Chemical, St. Louis, MO, USA) and 4 mg⁄mL of
dispase (Sigma-Aldrich, St. Louis, MO, USA) for 2 hours
at 37°C. Cells were dispersed into a six-well plate and in-
cubated in the lower sugar Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco BRL, Grand Island, NY, USA)
supplemented with 10% fasting blood sugar (FBS) (Gibco
BRL) for 3 days. The cultures were kept in an incubator
at 37°C and 5% CO2 with media changes three times per
week. When 70% to 80% confluence was reached, adher-
ent cells were detached with trypsin-EDTA (0.25%) and
passaged into fresh culture flasks at a ratio of 1:3. To
obtain homogeneous populations of PDLSCs, single-cell-
derived colony cultures were obtained by using a limit-
ing dilution technique.
MTT assay
Proliferative activities of rabbit PDLSCs were assessed
by using the MTT (3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide) assay as described previ-
ously [22]. Briefly, PDLSCs were seeded in 96-well
plates at a density of 2 × 103 cells per well and cultured
for 9 days. Twenty microliters of MTT solution (5 g/L)
was added to 10 of 90 wells each day, and the plates
were incubated for 4 hours at 37°C. Then, the medium
was replaced with 150 μL of dimethyl sulfoxide, and the
absorbance was measured at 490 nm by an enzyme-linked
immune detector.
Immunofluorescence staining
PDLSC identity was confirmed by immunocytochemical
staining by using the mouse antibodies against rabbit
vimentin and keratin (Boster Biological Technology Ltd.,
Wuhan, China) as well as human STRO-1 (R&D Sys-
tems, Inc., Minneapolis, MN, USA) at room temperature
for 2 hours. Cells were washed with phosphate-buffered
saline (PBS) and incubated with the fluorescein
isothiocyanate-conjugated anti-mouse IgG (1:100; Jack-
son ImmunoResearch Laboratories, Inc., West Grove,
PA, USA) for 1 hour at 37°C and then counterstained
with the nuclear dye 4′,6-diamidino-2-phenylindole
(DAPI) (Biotium, Hayward, CA, USA). The cells were
rinsed three times with PBS and analyzed by using a
DMIL fluorescent-inverted phase-contrast microscope
equipped with a Leica MPS-30 camera (Leica, Bensheim,
Germany).
Multipotent differentiation
To investigate the multipotency of PDLSCs, the ability
for isolated cells to undergo osteogenic and adipogenic
differentiation was tested. Multilineage differentiation
assays toward osteogenic and adipogenic pathways were
performed as previously reported [23]. To detect osteo-
genic differentiation, alkaline phosphatase (ALP) activity
was measured 3 and 7 days after seeding, in accordance
with the recommendations of the manufacturer. At the
21st day of differentiation, immunohistochemistry for
type I collagen and osteocalcin was performed on the
osteogenic stem cells prepared on chamber slides fixed
with 10% formalin. Calcium accumulation was detected
by staining with 2% Alizarin red S (Sigma-Aldrich)
(pH 4.2) on post-induction day 28. Adipogenesis was
assessed with Oil red O (Sigma Chemical) staining.
Constructs and cell transfection
Oligonucleotide design
A genomic sequence containing hOPG cDNA was synthe-
sized by Invitrogen Life Technologies Inc. (Gaithersburg,
MD, USA), according to the GenBank accession number
NM_002546, and cloned into intermediate vector contain-
ing pIRES-EGFP by using primers SF-F1 and SF-R1. The
flanking region of the primers (SF-F2 and SF-R2) was
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ual (Invitrogen, Carlsbad, CA, USA), as summarized in
Table 1.
Gateway cloning
Construct sequences (hOPG-pIRES-EGFP) were con-
firmed by sequencing and then amplified by using
primers SF-F2/SF-R2 for BP reaction, which generated
pDONR-hOPG-pIRES-EGFP, the entry clone in pDONR™
221 vector. BP reaction was followed by LR reaction in
accordance with the instructions of the vendor. Entry vec-
tor pDONR-hOPG-pIRES-EGFP was transferred to lenti-
virus expression vector pLenti6.3/V5-DEST to generate
pLenti6.3/V5-hOPG-pIRES-EGFP, the final expression
clone containing the N-terminal hOPG fusion. Both
the entry and expression clones were confirmed by au-
tomated DNA sequencing analysis (ABI 3730 DNA
analyzer; Applied Biosystems, Carlsbad, CA, USA).
Transfection into HEK293T and periodontal ligament stem
cells
The pLENT6.3/V5-hOPG-IRES-EGFP was firstly trans-
fected into the packaging cells HEK293T (Shanghai
Yingjun Bioengineering Co., Shanghai, China) by using
Lipofectamine2000 (Invitrogen) in accordance with the
instructions of the manufacturer. Infectious lentiviruses
were harvested after 48 hours, centrifuged to eliminate
cell debris, and filtered through 0.45-μm filters. The viral
titres were detected at 1.5 × 106 TU/mL by infecting
293 T cells with serial dilutions of concentrated lenti-
virus. Subsequently, the virus supernatants from infected
293 T-cell cultures were used to infect proliferating
PDLSCs at an optimized multiplicity of infection of 10
with polybrene (Sigma-Aldrich) at a final concentration
of 8.0 μg/mL, and the efficiency of transfection was de-
termined by using a fluorescent-inverted phase-contrast
microscope (Olympus, Tokyo, Japan).
Quantitative real-time reverse transcription-polymerase
chain reaction and Western blot
Two days after infection, the relative mRNA and protein
levels of hOPG were determined by Q-PCR and West-
ern blot. Total RNA was extracted by using the TRIzolTable 1 Primers used for Gateway cloning of human
osteoprotegerin into the lentiviral vector






CATCCATGCCGreagent (Gibco BRL). First-strand cDNA was synthesized
by using the SuperScript III First-Strand Synthesis System
(Invitrogen). Quantification of gene expression was carried
out by using Platinum Taq DNA Polymerase (Invitrogen,
São Paulo, Brazil). Protein hOPG quantification with
Western blot was performed as previously described [24].
All experiments were performed in triplicate, and the
mean value was recorded.
Transplantation of human osteoprotegerin-engineered
periodontal ligament stem cells
Seeding of beta-tricalcium phosphate
β-TCP (Shanghai Beiaolu Bio-Materials Ltd.) was prepared
before cell seeding as previously reported [10]. The
PDLSCs with or without hOPG-containing lentiviral vec-
tor transfection were collected via trypsinization and cen-
trifugation. The resuspended cells (5 × 106/mL) were then
seeded separately into sterile, resorbable β-TCP scaffolds.
Grafts were incubated for 2 hours at 37°C, allowing the
cells to adhere to β-TCP. After this incubation period,
cells were incubated in DMEM with 10% FBS at 37°C and
5% CO2. Morphological characterization of cells and ma-
terials was performed by using a Hitachi S-520 SEM
(Hitachi, Tokyo, Japan).
Generation of alveolar bone defect model
Twenty male New Zealand white rabbits were used to
generate a segmental critical-size alveolar bone defect
model as described previously [25]. All surgical proce-
dures were performed under general anesthesia with a
combination of sumianxin II (0.25 mL/kg) and pento-
barbital sodium (18 mg/kg) injected intramuscularly. A
10-mm incision was made, and the tissue overlying the
diaphysis of the left alveolar bone of incisors of rabbits
was dissected. A high-speed surgical bur, with copious
irrigation of sterile saline, was used during preparation
of the bony defects. The created alveolar bone defect
was 5 mm in width, 10 mm in length, and 4 mm in
depth (Figure 1).
Transplantation
After model generation, the defective samples in the
models were randomly assigned to four different treat-
ment groups (n = 5): (1) control group, no treatment;
(2) β-TCP group, transplantation of β-TCP scaffolds;
(3) PDLSCs/β-TCP group, transplantation of PDLSCs/β-
TCP constructs; and (4) hOPG-PDLSCs/β-TCP group,
transplantation of hOPG-transfected PDLSCs/β-TCP
constructs. All of the defects were covered with gelatin
membranes (Bio-Gide; Geistlich Biomaterials, Wolhusen,
Switzerland) and closed with sutures. All procedures were
carried out under aseptic conditions, and antibiotic was
given to each rabbit for 3 days after the surgery.
Figure 1 Schematic illustration of the generation of alveolar bone defects and transplantation of the tissue-engineered complex.
(A) The exposed rabbit alveolar bone. (B) Bone defects using a high-speed surgical bur supplemented with copious sterile saline water irrigation.
(C) The defect (10 × 5 × 4 mm) prepared in alveolar bone. (D) The tissue-engineered bone complex combined with or without periodontal
ligament stem cells inside alveolar bone defect. (E) Collagen membranes were placed to cover the implants and defects. (F) The defects were
closed with sutures.
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At 12 weeks after transplantation, all animals were
sacrificed and the mandibles were harvested. Periodon-
tal tissue samples were prepared by using the sawing-
grinding method as described by [26]. The blocks were
trimmed by using an exakt grinding machine (ExaktAp-
paratebau, Norderstedt, Germany), ground to a final
thickness of approximately 20 μm, and stained with
Toluidine blue, and the results were visualized by light
microscopy.
Laser confocal microscope
Periodontal tissue samples from the hOPG-PDLSCs/β-
TCP group were harvested, embedded in paraformalde-
hyde (4%) for 2 days, and prepared as described above.
The confocal images were obtained by using a laser con-
focal microscope system (TCS SP2; Leica).
Histomorphometric analysis
For morphometric analysis, three sequential sections per
implant were selected for evaluation. A histometricsoftware package with image-capturing capabilities
(Image-Pro Plus 6.0; Media Cybernetics Inc., Bethesda,
MD, USA) was used to evaluate the bone formation in
defects. The ratios between the regenerated bone area
and the total defect area of the images were calculated.
Statistical analysis
All statistical analyses were performed with SPSS version
17.0 (SPSS Inc., Chicago, IL, USA). Data are expressed
as mean ± standard deviation. The significance of differ-
ences between groups was evaluated by one-way analysis
of variance. A P value of less than 0.05 was considered
statistically significant.
Results
Culture and colony efficiency assays of periodontal
ligament cells
To isolate PDL cells, single-cell suspension was obtained
by enzymatic digestion and placed into the culture medium.
Primary PDL cells cultured by the tissue explant culture
method were adherent after 2 hours of culture, and the
Figure 2 Culture of periodontal ligament (PDL) cells from rabbits. (A) The PDL cells digested from rabbit periodontal tissue were cultured
for 10 days under a light microscope. (B) The morphology of the primary PDL cells under a light microscope. (C) Cell clone was established after
15 days of culture. (D) The isolated PDL cells grew vigorously after subculture. Magnification: 100 ×.
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in culture, primary PDL cells reached the edge of the
tissue block (Figure 2A). The isolated cells had typical
fibroblastic morphology, a spindle shape with extending
cytoplasmic processes (Figure 2B).
To obtain PDLSCs and determine the proliferation and
clonogenic potential of the cells, we performed a limiting
dilution assay using first-passage PDL cells. Clones were
evident after 15 days of culture, with a lot of small fusi-
form or triangular cells arranged closely (Figure 2C). The
PDL cells grew vigorously after subculture (Figure 2D).
Immunofluorescence analysis of PDLSCs showed positive
staining for vimentin but negative staining for keratin,
confirming their mesodermal origin (Figure 3A and B).
PDLSCs stained positively for STRO-1, confirming their
stromal stem cell status (Figure 3C).Figure 3 Immunocytochemical analysis of periodontal ligament stem
keratin. (C) STOR-1 was partially positively stained. DAPI (4′,6-diamidino-2-pOsteogenic and adipogenic differentiation of periodontal
ligament stem cells
To assess the multipotent capability of PDLSCs, cells
were cultured in osteogenic and adipogenic conditions
to induce differentiation of PDLSCs. Differentiation into
osteoblasts was confirmed by intense staining for ALP
(Figure 4A), Alizarin red (Figure 4B), OCN (Figure 4C),
and type I collagen (Figure 4D). Furthermore, ALP ac-
tivities varied during culture period (7 days) (Figure 4E).
ALP activities increased dramatically at day 7 compared
with those at day 3. There was no significant difference
of ALP activities at day 3 (P >0.05). ALP activities of the
cells in osteogenic condition were significantly higher
than those of the control group at day 7 (P <0.05). Differ-
entiation into adipocytes was confirmed by the presence
of fat vacuoles under a light microscope and Oil redcells. (A) Positive staining for vimentin. (B) Negative staining for
henylindole) was used for staining nuclei. Magnification: 100 ×.
Figure 4 In vitro osteogenesis of periodontal ligament stem cells. (A) Cells grown in osteogenic media stained positively for alkaline
phosphatase (ALP) (A) and Alizarin red (B) after 28 days of culture and for osteocalcin (C) and type I collagen (D) using immunocytochemistry
after 21 days of culture. (E) ALP activities in osteogenic condition increased significantly at day 7 when compared with that at day 3, but there
was no significant difference in ALP activities at days 3 and 7 in the control group. *P <0.05 versus control group. Magnifications: 100× (A, C) and
200× (B, D). OD, optical density.
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induction (Figure 5A and B).
Transfection of periodontal ligament stem cells
Lentiviral vector pLENTi6.3/V5-hOPG-IRES-EGFP con-
taining hOPG cDNA was successfully constructed and
transfected into PDLSCs. Within 48 hours after lentiviral
transfection, obvious green fluorescence expression can
be observed under fluorescence microscope (Figure 6).To investigate the effects of transfection of lentiviral
vector pLENTi6.3/V5-hOPG-IRES-EGFP on the expres-
sion of hOPG in PDLSCs, Q-PCR and Western blot were
used to quantify the mRNA and protein levels of hOPG in
the PDLSCs with or without OPG transfection, after
48 hours of culture. As shown in Table 2, the relative
mRNA level of OPG was significantly increased in hOPG-
transfected cells by 3,311.65-fold compared with the
mRNA expression levels of hOPG in non-transfected cells.
Figure 5 In vitro adipogenesis of periodontal ligament stem cells. Cells grown in adipogenic media demonstrate the presence of fat
vacuoles under a light microscope (A) and abundant fat vacuoles by Oil red O staining (B) after 6 weeks of culture. Magnification: 200 ×.
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IRES-EGFP transfected PDLSCs show that a band at 50
to 64 KD was observed at 72 hours after transfection
(Figure 7), and its size was consistent with the size of
hOPG fusion protein (60 kDa), indicating that hOPG
protein was expressed in PDLSCs.
Scanning electron microscopy
The images of β-TCP and PDLSCs/β-TCP constructs with
or without hOPG transfection were evaluated by SEM,
and results are presented in Figure 8. Under SEM, β-TCP
blocks showed three-dimensional open, network structure
with continuous void volume connecting adjacent pores
(Figure 8A). The PDLSCs with or without hOPG transfec-
tion were impregnated onto β-TCP porous scaffolds. After
2 days of culture, the PDLSCs could be seen adhered and
extended on the β-TCP surface and in the pore of the
scaffold material (Figure 8B and C). After 7 days of cul-
ture, a large number of PDLSCs could be seen adhered
and significantly grown in number to link flakiness on the
surface and in the pore of the scaffold material, and there
were many filarious extracellular matrices (Figure 8D and
E). No significant difference in growth of PDLSCs on β-
TCP was observed between the transfection group and
the non-transfection group.Figure 6 Images of periodontal ligament stem cells transfected with
(B) Fluorescent microscope image. Magnification: 100×. EGFP, enhanced gr
ribosome entry site.Histological analysis of in vivo studies
The PDLSCs with or without hOPG transfection were
impregnated onto β-TCP porous scaffolds, and cell/scaf-
fold constructs were implanted into alveolar bone de-
fects of rabbits. After 12 weeks, histological sections of
alveolar bone defects were analyzed for new bone forma-
tion. Toluidine blue staining showed that no bone regen-
eration was detected at the alveolar bone control group,
and there was remarkable ingrowth of muscle fibers into
the defect (Figure 9A). A small amount of new bone
could be seen in the β-TCP group, with some osteoid
formation in the periphery and center of the β-TCP scaf-
fold (Figure 9B and C). The PDLSCs/β-TCP group
showed more new alveolar bone formation, with numer-
ous small bone trusses or trabeculae interconnected with
each other (Figure 9D, E, and F). A maximal and robust
bone formation was presented in the hOPG-PDLSCs/β-
TCP group. Osteoblastic cells were lining the surface of
newly formed bone. Osseous maturation had increased,
with osteon formation and increased bone density
(Figure 9G, H, and I).
Circularly polarized light microscopy
To assess whether the hOPG-transfected PDLSCs/β-
TCP complex had implanted into the bone defects andpLENTi6.3/V5-hOPG-IRES-EGFP plasmid. (A) Bright field image.
een fluorescent protein; hOPG, human osteoprotegerin; IRES, internal
Table 2 Relative mRNA levels of human osteoprotegerin
in the transfection and non-transfection groups
Group Human osteoprotegerin mRNA (2−△△Ct)
Non-transfection 1
Transfection 3311.65
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samples from the hOPG-PDLSCs/β-TCP group were
first observed by using light microscopy to identify the
newly formed bone (Figure 10A). In the same visual
field, the hOPG-GFP-transfected PDLSCs were then ob-
served by fluorescence microscopy (Figure 10B). When
the images shown in Figure 10A and B were overlapped,
the positions of some GFP+ cells were superposed with
the osteoblasts and bone lacunas (Figure 10C). The
newly formed bone was also clearly observed in Tolui-
dine blue-stained tissue sections (Figure 10D). All of
these results indicated that the GFP+ cells derived from
ex vivo-expanded PDLSCs had differentiated into osteo-
blasts in vivo.Histomorphometric analysis
The results of histomorphometric analysis are summa-
rized in Figure 11. The percentage of new bone formed
area in the hOPG-transfected PDLSCs/β-TCP group was
significantly higher than that formed in the PDLSCs/β-
TCP group, the β-TCP group, and the control group.
This value for hOPG-transfected PDLSCs/β-TCP was
significantly higher than that for PDLSCs/β-TCP and β-
TCP (P <0.05), and the value for PDLSCs/β-TCP was
significantly higher than that for β-TCP (P <0.05).Figure 7 Western blot analysis of the expressions of human
osteoprotegerin (hOPG) in transfection and non-transfection
groups. Results show that hOPG-EGFP fusion gene was
co-expressed, suggesting that hOPG protein was successfully
expressed in periodontal ligament stem cells (PDLSCs). hOPG-PDLCs:
PDLSCs transfected with pLENTi6.3/V5-hOPG-IRES-EGFP plasmid; PDLCs:
control sample group: non-transfected PDLSCs. eGFP, enhanced green
fluorescent protein.Discussion
Alveolar bone destruction is a common hallmark of hu-
man periodontitis, a heterogeneous disease in etiology,
and is one of the major causes of tooth loss in humans
[27]. There appears to be an urgent need for the concept
of tissue and bone regeneration around implants because
of the increasing need to use dental implants for the
growing population of patients and to enhance their
function to simulate normal tooth physiology and pro-
prioception [6].
Tissue-engineering approaches, involving the utilization
of in vitro-expanded cells with regenerative capacity and
their delivery to the appropriate sites using biomaterial
scaffolds, have been proposed as promising alternatives
to conventional treatments [6,28]. Stem cell-based re-
generative approaches combined with the usage of
emerging biomaterials are entering a new era in peri-
odontal regeneration. PDL cells, in vitro-expanded cells
in sufficient quantities and possessing the potential to
regenerate alveolar bone and cementum, could be used
with appropriate biomaterials to engineer living tissues
in vitro for subsequent transplantation into defect sites
[29]. Meanwhile, the utilization of gene therapy to sus-
tain the release and bioavailability of osteogenic growth
factors also offers potential for periodontal tissue-
engineering and regeneration applications [30]. In this
study, we demonstrated that gene-modified rabbit
PDLSCs expressing hOPG combined with biodegrad-
able β-TCP scaffold achieved an earlier mineralization
and more bone formation when compared with β-TCP
and PDLSCs-β-TCP, which may help to ensure the re-
construction of alveolar bone defect.
MSCs are important cell resources for periodontal tis-
sue engineering; among them, PDLSCs are a candidate
cell source for periodontal regeneration and have proven
to be the ideal seeding cells for gene therapy in peri-
odontal tissue engineering [31]. Therefore, PDLSCs from
rabbit were used for periodontal tissue engineering in
this study. PDLSCs were isolated by a limiting dilution
method and were characterized by immunofluorescence
analysis. The validations of PDLSCs are important for
cytotherapeutic uses. For these reasons, we have associ-
ated STRO-1, vimentin, and keratin expressions to iso-
late a population of MSCs. The results showed that
PDLSCs were positively stained for STRO-1 and vimen-
tin and negatively for keratin, confirming their mesoder-
mal origin and stromal stem cell status. A significant
number of studies have been conducted to evaluate the
regenerative capacity of PDLSCs in vivo and in vitro,
and PDLSCs were demonstrated to differentiate into
many pathways under defined culture conditions [32].
Our study here showed that isolated PDLSCs represent
an approachable niche of stem cells when cultured in
conditioned media and are able to extensively proliferate
Figure 8 Images of β-TCP and PDLSCs/β-TCP constructs with or without hOPG transfection were evaluated by SEM. (A) Image of β-TCP
under SEM. (B, C) The PDLSCs adhered and extended on β-TCP surface after 2 days of culture. (D, E) The PDLSCs grew in number to link flakiness
on the β-TCP surface and in the pore of the scaffold material after 7 days of culture. Magnifications: 40× (A, B, D) and 400× (C, E). β-TCP, beta-tricalcium
phosphate; hOPG, human osteoprotegerin; PDLSC, periodontal ligament stem cell; SEM, scanning electron microscope.
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blasts, expressing osteogenic markers ALP, OCN, and
type I collagen as well as forming mineralized nodules
in vitro. Our single-colony-derived cells were also found
to be capable of differentiating into other cell lineages,
such as adipocytes, as demonstrated by the presence of
fat vacuoles and Oil red O-positive lipid droplets after
28 days of culture, confirming their pluripotent stem
origin. All of these results further confirmed that the
isolated cell population constitutes a large, ideal source of
osteoblasts, and the in vitro-expanded PDLSCs with regen-
erative capacity are suitable for bone regeneration, trans-
plantation, and tissue-based therapies.
The morphogenesis and remodeling of bone depend
on the integrated activity of osteoblasts that form bone
and osteoclasts that resorb bone [33]. OPG (or osteo-
clastogenesis inhibitory factor, OCIF), a naturally occur-
ring secreted protein with homology to members of the
TNF receptor family, is a soluble decoy receptor for
RANKL, a critical osteoclast differentiation factor that
selectively inhibited osteoclast differentiation and func-
tion in vitro and in vivo [34,35]. Administration of OPG
in vivo has been shown to inhibit osteoclastogenesis and
associated bone resorption and blocks the pathological
increase in osteoclast numbers and activity seen in ani-
mal models that mimic osteopenic disorders in humans
[36]. In vivo inhibition of OPG function with OPG lig-
and diminished alveolar bone destruction and reducesthe number of periodontal osteoclasts after microbial
challenge [19]. Systemic administration of OPG interfer-
ing with RANKL abrogated periodontal bone resorption
in the rat model, and treatment with kaliotoxin, a scor-
pion venom potassium channel inhibitor, resulted in
decreased RANKL expression, diminished induction of
RANKL-dependent osteoclastogenesis, and abrogation
of bone resorption [37]. However, the latter was also re-
ported to be abrogated by OPG fusion protein [38].
Therefore, hOPG may promise tremendous hope for po-
tential clinical use in the management of human peri-
odontal disease.
However, in human clinical trials, direct application of
OPG may be limited in action. A major problem that
needed to be overcome is how to localize the delivery of
this short half-lived factor to target cells since large
doses of this factor in treatment can result in adverse
side effects [39,40]. Thus, maintaining systemically
stable, therapeutic levels of OPG will be critical for
preventing osteolytic bone damage. To address this
problem and to acquire localized, continuous expres-
sion of OPG in target cells and tissue, increasing atten-
tion has been focused on the use of gene therapy
technique [17,41]. The use of gene therapy technique
is more advantages in the local expression than continu-
ously injecting OPG or recombinant protein, and
appears to be a highly promising adjuvant therapy to
this end.
Figure 9 Histological sections stained by Toluidine blue of the alveolar bone defects at 12 weeks after implantation. (A) No bone
regeneration was detected at the alveolar bone control group. A small amount of new bone could be seen in the β-TCP group, with some
osteoid formation in the periphery and center of the β-TCP scaffold (B, C). The PDLSCs/β-TCP group showed more new alveolar bone formation,
with numerous small bone trusses or trabeculae interconnected with each other (D-F). A maximal and robust bone formation was presented in
the hOPG-PDLSCs/β-TCP group. Osteoblastic cells were lining the surface of newly formed bone. Osseous maturation had increased, with osteon
formation and increased bone density (G-I). Magnifications: 40× (A, B, D, G), 100× (E), and 400× (C, F, H, I). β-TCP, beta-tricalcium phosphate;
hOPG, human osteoprotegerin; PDLSC, periodontal ligament stem cell.
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cally in a sustained manner is important for effective tis-
sue regenerations, and the efficacy of a combinatorial
gene and cell therapeutic approach also depends on
transgene expression vector. Reporter genes, like eGFP, a
chromophore-containing protein, have generally been
used for the gene expression and regulation to deter-
mine the efficiency of gene vector delivery [20]. After
direct comparison of different gene therapy vectors in
the stem cell preparation, McMahon et al. [42] indicated
that lentivirus was the most effective vector for stem cell
transduction and that high and moderate levels of cell
transduction using lentivirus vectors did not affect the
ability of the cells to differentiate down the adipogenic
pathway. Corroborating these results, Wen et al. [31]
(2012) demonstrated that lentiviral vector with eGFPwas an appropriate expression vector system and that
human PDLSCs were ideal seeding cells for gene therapy
in periodontal tissue engineering. Therefore, in this
study, lentiviral vector pLenti6.3/V5-DEST containing
eGPF and hOPG was constructed by using Gateway
cloning technology for gene therapy, and the expressions
of hOPG were shown to be significantly enhanced in
both mRNA and protein levels after transfection into
rabbit PDLSCs.
In addition to the preparation of PDLSCs and construc-
tion of hOPG-engineered lentiviral vector, the develop-
ment of suitable bioactive three-dimensional scaffolds for
promotion of cellular proliferation and differentiation is
critical in periodontal tissue engineering. β-TCP has been
shown to have good biocompatibility and osteoconductiv-
ity in both animal experiments and clinical settings [8,10].
Figure 10 New bone regeneration assessment of hOPG-transfected PDLSCs/β-TCP constructs by circularly polarized light microscopy.
(A) The osteoblasts and bone lacunas were clearly observed in the newly formed bone by using light microscopy. (B) At the same visual field,
the hOPG-GFP-transfected PDLSCs were observed by using a fluorescence microscope. (C) When images (A) and (B) were overlapped, the
positions of some GFP+ cells were superposed with the osteoblasts and bone lacunas. The newly formed bone was also clearly observed in
Toluidine blue-stained tissue sections (D). Magnification: 100×. β-TCP, beta-tricalcium phosphate; GFP, green fluorescent protein; hOPG, human
osteoprotegerin; PDLSC, periodontal ligament stem cell.
Figure 11 Histomorphometric findings of new bone formation
(percentage) in the constructs after 12 weeks of implantation
(n = 5). *P <0.05 versus the control group; +P <0.05 versus the β-TCP
group; #P <0.05 versus the PDLSCs/β-TCP group. β-TCP, beta-tricalcium
phosphate; EGFP, enhanced green fluorescent protein; OPG,
osteoprotegerin; PDLSC, periodontal ligament stem cell.
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rabbit PDLSCs with or without engineered hOPG were
seeding on β-TCP scaffolds. SEM results showed that
β-TCP blocks were three-dimensional open, network
structure with continuous void volume connecting
adjacent pores. The PDLSCs with or without hOPG
transfection were impregnated onto β-TCP porous scaf-
folds. After 7 days of culture, a large number of PDLSCs
could be seen adhered and significantly grown in number
to link flakiness on the surface and in the pore of scaffold
material, and there were many filarious extracellular
matrices. Interestingly, no significant difference in growth
of PDLSCs on β-TCP was observed between transfection
and non-transfection groups. These results demonstrated
that β-TCP supported the attachment, growth, and differ-
entiation of PDLSCs and possessed good biocompatibility.
To further assess the hOPG-engineered PDLSCs-β-TCP
complex on alveolar bone regeneration, we implanted β-
TCP with or without PDLSCs as well as hOPG-engineered
PDLSCs-β-TCP complex into the alveolar bone defect
rabbit models. After 12 weeks, histological sections of al-
veolar bone defects were analyzed for new bone formation.
Toluidine blue staining showed that hOPG-engineered
Su et al. Stem Cell Research & Therapy  (2015) 6:22 Page 13 of 14PDLSCs-β-TCP tissue-engineered complex had an earlier
mineralization and more bone formation inside the scaffold
than control, β-TCP, and PDLSCs-β-TCP. The results indi-
cated that alveolar bone repair was significantly enhanced
when PDLSCs cultured on β-TCP were transfected with
exogenous hOPG in vivo. Several studies have also demon-
strated, even without the artificial extracellular matrix sub-
stitutes and the three-dimensional environment used for
cell culture, that bone repair is significantly enhanced when
OPG delivery is supplemented with osteogenic cell popula-
tions [17,41]. MSC genes modified with OPG were also
reported to be able to reverse osteoclast activation in a
xenogeneic model of multiple myeloma [38]. All of these
results suggested that the local stem cell niche is a limiting
factor and that the implanted scaffold with PDLSCs engi-
neered by hOPG could create enough extracellular cell
matrix for adequate healing.
Meanwhile, circularly polarized light microscopy re-
sults further confirmed the success of hOPG-transfected
PDLSCs-β-TCP complex implantation into rabbit bone
defects of rabbits and osteoblast differentiation in vivo.
The new bone formation in defects was evaluated
by using histomorphometric analysis. Results showed
that the percentage of new bone formed area in the
hOPG-transfected PDLSCs-β-TCP group was signifi-
cantly higher than that in the PDLSCs-β-TCP group, the
β-TCP group, and the control group, suggesting that
hOPG-transfected PDLSCs-β-TCP complex could very
well integrate into host alveolar bone and could be used
as a promising tissue-engineering technology for alveolar
bone regeneration.Conclusions
The present study demonstrated the feasibility of using
β-TCP scaffolds for primary PDLSC culture and expres-
sion of hOPG gene in vitro and in vivo, and the β-TCP
scaffolds containing hOPG-engineered PDLSCs exhibited
the highest proliferation rate and an earlier mineralization
and more bone formation inside the scaffold. The above
results suggested the potential of systemic hOPG gene
therapy in combination with PDLSC tissue engineering
as a good candidate in periodontal tissue engineering
for alveolar bone regeneration.Abbreviations
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